Skip to main content

Publications

Found 134 results
Author [ Title(Desc)] Year
Filters: Keyword is Pregnancy  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
De Silva D, Sawchuck D, von Dadelszen P, Basso M, Synnes A, Liston R, et al.. Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87.  (362.1 KB)
Bickford C, Magee LA, Mitton C, Kruse M, Synnes A, Sawchuck D, et al.. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527.  (2 MB)
Teela K, De Silva D, Chapman K, Synnes A, Sawchuck D, Basso M, et al.. Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347.  (549.75 KB)
De Silva D, Synnes A, von Dadelszen P, Lee T, Bone J, Magee LA. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada. Implement Sci. 2018;13(1):8.  (1.89 MB)
Gordon R, Magee LA, Payne BA, Firoz T, Sawchuck D, Tu D, et al.. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163.  (1.42 MB)
Management of the second stage of labor. Int J Gynaecol Obstet. 2012;119(2):111-6.  (468.69 KB)
Bellad M, Vidler M, Honnungar N, A M, Ramadurg U, Charanthimath U, et al.. Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623.  (2.12 MB)
Goudar S, Carlo W, McClure E, Pasha O, Patel A, Esamai F, et al.. The Maternal and Newborn Health Registry Study of the Global Network for Women's and Children's Health Research. Int J Gynaecol Obstet. 2012;118(3):190-3.  (98.99 KB)
Lissauer D, Kilby M, Moss P. Maternal effector T cells within decidua: The adaptive immune response to pregnancy?. Placenta. 2017;60:140-144.  (435.5 KB)
Gammill H, Harrington W. Microchimerism: Defining and redefining the prepregnancy context - A review. Placenta. 2017;60:130-133.  (200.23 KB)
Burton G, Yung H, Murray A. Mitochondrial - Endoplasmic reticulum interactions in the trophoblast: Stress and senescence. Placenta. 2017;52:146-155.  (3.07 MB)
von Dadelszen P, Magee LA, Payne BA, Dunsmuir D, Drebit S, Dumont G, et al.. Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5.  (662.6 KB)
Aarvold A, Ryan H, Magee LA, von Dadelszen P, Fjell C, Walley K. Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Crit Care Med. 2017;45(1):e49-e57.  (910.16 KB)
P
Lawrie T, Betrán A, Singata-Madliki M, Ciganda A, Hofmeyr J, Belizan J, et al.. Participant recruitment and retention in longitudinal preconception randomized trials: lessons learnt from the Calcium And Pre-eclampsia (CAP) trial. Trials. 2017;18(1):500.  (392.56 KB)
Payne BA, Hodgson S, Hutcheon J, Joseph KS, Li J, Lee T, et al.. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.  (85.31 KB)
Steegers-Theunissen R. Periconception mHealth platform for prevention of placental-related outcomes and non-communicable diseases. Placenta. 2017;60:115-118.  (428.43 KB)
Lalani S, Firoz T, Magee LA, Sawchuck D, Payne BA, Gordon R, et al.. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.  (529.81 KB)
Firoz T, Magee LA, Payne BA, Menzies J, von Dadelszen P. The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81.  (233.18 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Benton S, McCowan L, Heazell AEP, Grynspan D, Hutcheon J, Senger C, et al.. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.  (475.29 KB)
Ukah V, Hutcheon J, Payne BA, Haslam M, Vatish M, Ansermino JM, et al.. Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237.  (986.49 KB)
Salam R, Qureshi R, Sheikh S, Khowaja A, Sawchuck D, Vidler M, et al.. Potential for task-sharing to Lady Health Workers for identification and emergency management of pre-eclampsia at community level in Pakistan. Reprod Health. 2016;13(Suppl 2):107.  (286.51 KB)
Akkermans J, Payne BA, von Dadelszen P, Groen H, de Vries J, Magee LA, et al.. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.  (317.15 KB)
Ukah V, De Silva D, Payne BA, Magee LA, Hutcheon J, Brown H, et al.. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123.  (501.41 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)

Pages